Goldman Sachs Maintains Neutral on Cue Health, Lowers Price Target to $0.5
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a Neutral rating on Cue Health (NASDAQ:HLTH) and reduced the price target from $0.75 to $0.5. This adjustment reflects a more conservative valuation of the company's stock.
November 10, 2023 | 3:58 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Cue Health but lowered the price target from $0.75 to $0.5, indicating a potential downside or limited upside for the stock.
The reduction in price target by a major analyst like Goldman Sachs suggests a bearish outlook on the stock's value, which could lead to a negative short-term impact on the stock price as market participants adjust their expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100